Saltar al contenido
Merck

TRIM7 inhibits enterovirus replication and promotes emergence of a viral variant with increased pathogenicity.

Cell (2021-06-02)
Wenchun Fan, Katrina B Mar, Levent Sari, Ilona K Gaszek, Qiang Cheng, Bret M Evers, John M Shelton, Mary Wight-Carter, Daniel J Siegwart, Milo M Lin, John W Schoggins
RESUMEN

To control viral infection, vertebrates rely on both inducible interferon responses and less well-characterized cell-intrinsic responses composed of "at the ready" antiviral effector proteins. Here, we show that E3 ubiquitin ligase TRIM7 is a cell-intrinsic antiviral effector that restricts multiple human enteroviruses by targeting viral 2BC, a membrane remodeling protein, for ubiquitination and proteasome-dependent degradation. Selective pressure exerted by TRIM7 results in emergence of a TRIM7-resistant coxsackievirus with a single point mutation in the viral 2C ATPase/helicase. In cultured cells, the mutation helps the virus evade TRIM7 but impairs optimal viral replication, and this correlates with a hyperactive and structurally plastic 2C ATPase. Unexpectedly, the TRIM7-resistant virus has a replication advantage in mice and causes lethal pancreatitis. These findings reveal a unique mechanism for targeting enterovirus replication and provide molecular insight into the benefits and trade-offs of viral evolution imposed by a host restriction factor.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-β-actina monoclonal, clone AC-15, purified from hybridoma cell culture
Sigma-Aldrich
Anticuerpo anti-virus de Coxsackie B3, clon 280-5F-4E-5E, clone 280-5F-4E-5E, Chemicon®, from mouse